BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab

Mise à jour : Il y a 4 ans
Référence : NCT02054481

Femme et Homme

Extrait

The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066 in adult patients with chronic plaque psoriasis in order to select doses for further clinical trials.


Critère d'inclusion

  • Psoriasis


Liens